Management of Hepatic Granulomatous Tuberculosis After BCG Therapy for Bladder Cancer

Mohsen Ayati; Mohammad Reza Nowroozi; Afshin Mortazavi; Solmaz Ohadian Moghadam; Hossein Ghorani

doi:10.1016/j.eucr.2017.04.011

Management of Hepatic Granulomatous Tuberculosis After BCG Therapy for Bladder Cancer

Urol Case Rep. 2017 May 25:13:158-159. doi: 10.1016/j.eucr.2017.04.011. eCollection 2017 Jul.

Authors

Mohsen Ayati¹, Mohammad Reza Nowroozi¹, Afshin Mortazavi¹, Solmaz Ohadian Moghadam¹, Hossein Ghorani¹

Affiliation

¹ Uro-Oncology Research Center, Tehran University of Medical Sciences, Tehran, Iran.

Abstract

BCG therapy is used as a treatment in bladder cancer. Intravesical administration of Bacillus Calmette-Guérin is used as a treatment method in superficial bladder cancer. While it is commonly effective, some serious side effects may occur. We hereby report a 65-year-old man who developed granulomatous hepatitis as a complication following BCG therapy. He was treated successfully with antitubercular therapy and prednisolone.

Keywords: BCG therapy; Bladder cancer; Hepatic granulomatous tuberculosis.

Publication types

Case Reports